首頁 > 市場調查報告書 > 製藥

眼科藥物

乾眼症治療市場到2030年預測：按產品類型、治療、給藥、藥物、診斷、藥物類型、配銷通路、最終用戶和地區進行的全球分析

市場調查報告書

商品編碼

1383363

乾眼症治療市場到2030年預測：按產品類型、治療、給藥、藥物、診斷、藥物類型、配銷通路、最終用戶和地區進行的全球分析

Dry Eye Syndrome Treatment Market Forecasts to 2030 - Global Analysis By Product Type, Treatment, Dose, Drug, Diagnosis, Medication Type, Distribution Channel, End User and By Geography

出版日期: 2023年11月01日 | 出版商:

Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的資料，2023年全球乾眼症治療市場規模將達到 51 億美元，預計到2030年將達到 94 億美元，預測期內年複合成長率為 9.1%。

乾眼症，或稱為乾性角膜結膜炎（KCS）的疾病，其特徵是眼睛表面缺乏潤滑或水分。乾眼症是一種普遍存在的疾病，可以隨時影響任何人。其他乾眼症狀包括畏光、疼痛或灼熱感、眼睛疼痛、發紅、眼睛疲勞、眼睛發癢和其他與眼睛相關的問題。流淚也是乾燥的徵兆，因為眼睛表面的乾燥會過度刺激淚液中水分的產生。

根據領先的眼保健公司 Bausch & Lomb 的投資者介紹，估計美國有 3800 萬人患有乾眼症，但其中只有 1900 萬人被診斷出來。

乾眼症呈上升趨勢

隨著年齡的成長，這種慢性疾病對人們的影響有所不同。由於飲食不良，隱形眼鏡使用增加，看螢幕時間增加以及LASIK手術增加等因素，乾眼症在年輕人和老年人群中的患病率都在增加。隨著乾眼症盛行率的上升，對該疾病採取更強化治療性介入的需求將會增加，並可能推動乾眼症市場在預測期內的擴張。

眼睛健康不被重視

人們很少定期去看眼科醫生，除非他們有嚴重的臨床問題。乾眼症狀，例如發紅和灼熱感，常常未被診斷出來。因此，可以使用這些處方藥物治療的患者越來越少。因此，這些眼部護理產品的接受度下降，市場拓展潛力有限。

增加研發活動

由於建立高效治療線的大量研發投資，乾眼症治療市場日益擴大。隨著LASIK手術的增加，對乾眼症治療的需求不斷增加。先進技術開發投資的增加和新興市場數量的增加預計也將在預測期內推動市場成長。

缺乏意識

大眾對眼睛健康知之甚少。乾眼症的許多症狀鮮為人知，但透過正確的診斷和藥物治療可以快速治癒或緩解。除非有重大臨床問題，否則患者很少去看眼科。對於許多乾眼症患者來說，發紅、發炎和其他症狀被忽視或誤診，減少了接受處方藥物治療的人數。這阻礙了市場的拓展。

COVID-19 的影響：

大流行期間進行的大量研究發現，乾眼症狀在康復後持續數週或數月。這是一種常見的眼病，導致這種疾病的盛行率增加。此外，隨著COVID-19的出現，人們的工作和學習習慣逐漸從線下轉移到線上，導致疾病的盛行率上升。另一方面，發現疫情期間，非必要治療性介入的諮詢減少，對這些治療的需求也減少。

預計環孢素部門在預測期內將是最大的

由於環孢素類藥物的長期使用，預計環孢素細分市場在預測期內將成為最大的細分市場。研究表明，它有助於治療乾眼症的徵兆和症狀。據報導，環孢菌素可以減少 T 細胞增殖，這是一種導致該疾病的發炎反應。 Restasis 和 Cequa 是 FDA 核准的乾眼治療藥物。

醫院藥房業務預計在預測期內年複合成長率最高

由於對乾眼診斷和治療的設備和藥物的需求不斷增加，醫院藥學產業預計在預測期內將出現最高的年複合成長率。醫院藥劑師經常治療需要專科治療的嚴重或複雜乾眼症患者。這些患者可能會受益於服用處方藥，例如免疫調節劑和發炎藥，這些藥物通常在醫院藥房出售。

佔有率最大的地區：

預計北美在預測期內將佔據最大的市場佔有率。這種高市場佔有率可歸因於多種因素，包括重要行業參與企業的出現、乾眼患者數量的增加以及老年人口的擴大。由於高齡化、數位設備的廣泛普及和環境因素等多種因素，該地區乾眼症的盛行率相對較高。

年複合成長率最高的地區：

由於整體醫療基礎設施的改善，乾眼患者病率的上升以及醫療保健可及性的改善，預計亞太地區在預測期內將保持最高的年複合成長率。在中國和印度等人口大國，心血管疾病的盛行率很高，市場參與企業不斷增加的策略和趨勢，如產品開拓、產品核可、聯盟、合作和協議，推動該地區的擴張。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

公司簡介
- 其他市場參與企業的綜合分析（最多 3 家公司）
- 主要企業SWOT分析（最多3家企業）
區域細分
- 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
競爭基準化分析
- 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 義大利
- 法國
- 西班牙
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 紐西蘭
- 韓國
- 其他亞太地區
南美洲
- 阿根廷
- 巴西
- 智利
- 南美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 卡達
- 南非
- 中東和非洲其他地區

第14章進展

合約、夥伴關係、協作和合資企業
收購和合併
新產品發布
業務擴展
其他關鍵策略

第15章公司簡介

Novartis AG
Eli Lilly and Company
AbbVie, Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Sanofi
Santen Pharmaceutical Co., Ltd.
Pfizer Inc.
AFT Pharmaceuticals
Merck & Co., Inc.
Johnson & Johnson Services, Inc.
Akorn Operating Company LLC
Bausch+Lomb Corporation
Allergan
OASIS Medical
GlaxoSmithKline plc
Oyster Point Pharma, Inc.
Otsuka America Pharmaceutical, Inc.
Novaliq GmbH
F. Hoffmann-La Roche Ltd.

簡介目錄圖表

Product Code: SMRC24213

According to Stratistics MRC, the Global Dry Eye Syndrome Market is accounted for $5.1 billion in 2023 and is expected to reach $9.4 billion by 2030 growing at a CAGR of 9.1% during the forecast period. The disease known as dry eye syndrome, or keratoconjunctivitis sicca (KCS), is characterized by a lack of lubrication or moisture on the eye's surface. It is a widespread condition that can affect anyone at any time. Other dry eye symptoms include photophobia, aching and burning feelings, hurting eyes, red eyes, fatigued eyes, itchy eyes, and other eye-related issues. Watery eyes can also be a sign because the dryness of the eye's surface over-stimulates the creation of the watery component of tears.

According to investor presentation of Bausch + Lomb, a leading eye care company, in U.S. an estimated 38 million people affected with dry eye disease (DED) out of which only 19 million were diagnosed.

Market Dynamics:

Driver:

Growing prevalence of dry eye syndrome

This chronic illness affects people differently as they age. The prevalence is rising in both the young and the elderly population, though, as a result of bad food, increased use of contact lenses, more screen time, and an increase in LASIK procedures. The need for more potent treatment interventions for this illness will rise as its prevalence rises, fueling the expansion of the dry eye syndrome market throughout the projected period.

Restraint:

Low priority given to eye health

Unless there is a severe clinical problem, people seldom consult ophthalmologists on a regular basis. It happens frequently that dry eye symptoms like redness, burning, and other similar ones go undiagnosed. The number of patients who can be treated with these prescription medications as a result of this has decreased. The market expansion potential is therefore limited as a result of the lower acceptance rate of these eye care products.

Opportunity:

Increase in the number of R & D activities

The market for treating dry eye problems is expanding as a consequence of the high R&D investment on the creation of efficient treatment lines. As the country performs more LASIK surgeries, there is a growing demand for treatments for dry eye syndrome. Rising investments in the development of advanced technologies and an increase in the number of emerging markets will also help the market grow during the forecast period.

Threat:

Lack of awareness

The general public knows virtually little about eye health. Many of the symptoms of dry eyes, which may be swiftly cured or relieved with a correct diagnosis and medications, are not well known. Patients rarely visit ophthalmologists unless there is a major clinical problem. Many dry eye sufferers have their redness, irritation, and other symptoms ignored or misdiagnosed, which reduces the number of individuals who may receive prescription pharmaceutical treatment. This is limiting the market from expanding.

COVID-19 Impact:

Numerous investigations conducted during the pandemic discovered that individuals continued to experience dry eye symptoms for several weeks or months after they had recovered. As this is a prevalent ophthalmic disorder, this resulted in a rise in the prevalence of this ailment. Additionally, during the COVID-19, a gradual transition in people's work and study habits from offline to online led to a rise in the prevalence of this disorder. On the other hand, it was discovered that throughout the pandemic, consultations for all non-essential therapeutic interventions had decreased, which led to a fall in the demand for these therapies.

The cyclosporine segment is expected to be the largest during the forecast period

The cyclosporine segment is expected to be the largest during the forecast period owing to the long-standing use of medications using cyclosporine as a basis. Research has shown its usefulness for treating the signs and symptoms of dry eye illness. Cyclosporine has been reported to decrease T-cell proliferation, an inflammatory response that contributes to disease. Restasis and Cequa are two drugs for treating the symptoms of dry eye that have FDA approval.

The hospital pharmacy segment is expected to have the highest CAGR during the forecast period

The hospital pharmacy segment is expected to have the highest CAGR during the forecast period owing to increasing demand for devices and drugs for the diagnosis and treatment of dry eye disease. Patients with more severe or complicated instances of dry eye disease who needs specialist care are frequently catered to by hospital pharmacists. These patients may benefit from taking prescription drugs like Immunomodulators or anti-inflammatory drugs, which are commonly sold at hospital pharmacies.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. This high market share may be ascribed to a variety of factors, including the presence of significant industry players, an increase in the number of patients suffering from dry eye disease, an expanding elderly population, among others. This region has a relatively high prevalence of dry eye disease, driven by various factors such as an aging population, widespread use of digital devices, and environmental factors.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to improvements in overall healthcare infrastructure, rising prevalence of dry eye disease, and improved access to healthcare. The high prevalence of cardiovascular diseases in countries with high populations, such as China and India, as well as the rising number of market players' strategies and trends, such as product development, product approval, partnership, collaboration, and agreement, are driving the region to expand.

Key players in the market

Some of the key players in Dry Eye Syndrome market include: Novartis AG, Eli Lilly and Company, AbbVie, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi, Santen Pharmaceutical Co., Ltd., Pfizer Inc ., AFT Pharmaceuticals, Merck & Co., Inc. , Johnson & Johnson Services, Inc., Akorn Operating Company LLC , Bausch + Lomb Corporation, Allergan, OASIS Medical, GlaxoSmithKline plc, Oyster Point Pharma, Inc., Otsuka America Pharmaceutical, Inc., Novaliq GmbH and F. Hoffmann-La Roche Ltd.

Key Developments:

In June 2023, Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.

In May 2023, Bausch + Lomb Corporation and Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) has approved MIEBO (perfluorohexyloctane ophthalmic solution; formerly known as NOV03), for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only FDA-approved treatment for DED that directly targets tear evaporation.

Product Types Covered:

Artificial Tears
Cyclosporine
Lubricants
Corticosteroids
Punctual Bags
Omega Supplements
Other Product Types

Treatments Covered:

Anti-Inflammatory
Cholinergics
Anti-Infectives
Lubricating Agent
Anti-Allergics
Other Treatments

Doses Covered:

Multi Dose
Unit Dose

Drugs Covered:

Xiidra
Restasis
Cequa
Eysuvis
Tyrvaya
Other Drugs

Diagnosis Covered:

Tear Osmolarity Test
Schirmer Test
Comprehensive Eye Exam

Medication Types Covered:

Over the counter (OTC) Drug
Prescription (Rx) Drug
Other Medication Types

Distribution Channels Covered:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

End Users Covered:

Homecare
Hospitals
Specialty Clinics
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Dry Eye Syndrome Treatment Market, By Product Type

5.1 Introduction
5.2 Artificial Tears
5.3 Cyclosporine
5.4 Lubricants
5.5 Corticosteroids
5.6 Punctual Bags
5.7 Omega Supplements
5.8 Other Product Types

6 Global Dry Eye Syndrome Treatment Market, By Treatment

6.1 Introduction
6.2 Anti-Inflammatory
6.3 Cholinergics
6.4 Anti-Infectives
6.5 Lubricating Agent
6.6 Anti-Allergics
6.7 Other Treatments

7 Global Dry Eye Syndrome Treatment Market, By Dose

7.1 Introduction
7.2 Multi Dose
7.3 Unit Dose

8 Global Dry Eye Syndrome Treatment Market, By Drug

8.1 Introduction
8.2 Xiidra
8.3 Restasis
8.4 Cequa
8.5 Eysuvis
8.6 Tyrvaya
8.7 Other Drugs

9 Global Dry Eye Syndrome Treatment Market, By Diagnosis

9.1 Introduction
9.2 Tear Osmolarity Test
9.3 Schirmer Test
9.4 Comprehensive Eye Exam

10 Global Dry Eye Syndrome Treatment Market, By Medication Type

10.1 Introduction
10.2 Over the counter (OTC) Drug
10.3 Prescription (Rx) Drug
10.4 Other Medication Types

11 Global Dry Eye Syndrome Treatment Market, By Distribution Channel

11.1 Introduction
11.2 Hospital Pharmacy
11.3 Retail Pharmacy
11.4 Online Pharmacy

12 Global Dry Eye Syndrome Treatment Market, By End User

12.1 Introduction
12.2 Homecare
12.3 Hospitals
12.4 Specialty Clinics
12.5 Other End Users

13 Global Dry Eye Syndrome Treatment Market, By Geography

13.1 Introduction
13.2 North America
- 13.2.1 US
- 13.2.2 Canada
- 13.2.3 Mexico
13.3 Europe
- 13.3.1 Germany
- 13.3.2 UK
- 13.3.3 Italy
- 13.3.4 France
- 13.3.5 Spain
- 13.3.6 Rest of Europe
13.4 Asia Pacific
- 13.4.1 Japan
- 13.4.2 China
- 13.4.3 India
- 13.4.4 Australia
- 13.4.5 New Zealand
- 13.4.6 South Korea
- 13.4.7 Rest of Asia Pacific
13.5 South America
- 13.5.1 Argentina
- 13.5.2 Brazil
- 13.5.3 Chile
- 13.5.4 Rest of South America
13.6 Middle East & Africa
- 13.6.1 Saudi Arabia
- 13.6.2 UAE
- 13.6.3 Qatar
- 13.6.4 South Africa
- 13.6.5 Rest of Middle East & Africa

14 Key Developments

14.1 Agreements, Partnerships, Collaborations and Joint Ventures
14.2 Acquisitions & Mergers
14.3 New Product Launch
14.4 Expansions
14.5 Other Key Strategies

15 Company Profiling

15.1 Novartis AG
15.2 Eli Lilly and Company
15.3 AbbVie, Inc.
15.4 Teva Pharmaceutical Industries Ltd.
15.5 Sun Pharmaceutical Industries Ltd.
15.6 Sanofi
15.7 Santen Pharmaceutical Co., Ltd.
15.8 Pfizer Inc.
15.9 AFT Pharmaceuticals
15.10 Merck & Co., Inc.
15.11 Johnson & Johnson Services, Inc.
15.12 Akorn Operating Company LLC
15.13 Bausch + Lomb Corporation
15.14 Allergan
15.15 OASIS Medical
15.16 GlaxoSmithKline plc
15.17 Oyster Point Pharma, Inc.
15.18 Otsuka America Pharmaceutical, Inc.
15.19 Novaliq GmbH
15.20 F. Hoffmann-La Roche Ltd.

簡介目錄圖表

List of Tables

Table 1 Global Dry Eye Syndrome Treatment Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Dry Eye Syndrome Treatment Market Outlook, By Product Type (2021-2030) ($MN)
Table 3 Global Dry Eye Syndrome Treatment Market Outlook, By Artificial Tears (2021-2030) ($MN)
Table 4 Global Dry Eye Syndrome Treatment Market Outlook, By Cyclosporine (2021-2030) ($MN)
Table 5 Global Dry Eye Syndrome Treatment Market Outlook, By Lubricants (2021-2030) ($MN)
Table 6 Global Dry Eye Syndrome Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 7 Global Dry Eye Syndrome Treatment Market Outlook, By Punctual Bags (2021-2030) ($MN)
Table 8 Global Dry Eye Syndrome Treatment Market Outlook, By Omega Supplements (2021-2030) ($MN)
Table 9 Global Dry Eye Syndrome Treatment Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 10 Global Dry Eye Syndrome Treatment Market Outlook, By Treatment (2021-2030) ($MN)
Table 11 Global Dry Eye Syndrome Treatment Market Outlook, By Anti-Inflammatory (2021-2030) ($MN)
Table 12 Global Dry Eye Syndrome Treatment Market Outlook, By Cholinergics (2021-2030) ($MN)
Table 13 Global Dry Eye Syndrome Treatment Market Outlook, By Anti-Infectives (2021-2030) ($MN)
Table 14 Global Dry Eye Syndrome Treatment Market Outlook, By Lubricating Agent (2021-2030) ($MN)
Table 15 Global Dry Eye Syndrome Treatment Market Outlook, By Anti-Allergics (2021-2030) ($MN)
Table 16 Global Dry Eye Syndrome Treatment Market Outlook, By Other Treatments (2021-2030) ($MN)
Table 17 Global Dry Eye Syndrome Treatment Market Outlook, By Dose (2021-2030) ($MN)
Table 18 Global Dry Eye Syndrome Treatment Market Outlook, By Multi Dose (2021-2030) ($MN)
Table 19 Global Dry Eye Syndrome Treatment Market Outlook, By Unit Dose (2021-2030) ($MN)
Table 20 Global Dry Eye Syndrome Treatment Market Outlook, By Drug (2021-2030) ($MN)
Table 21 Global Dry Eye Syndrome Treatment Market Outlook, By Xiidra (2021-2030) ($MN)
Table 22 Global Dry Eye Syndrome Treatment Market Outlook, By Restasis (2021-2030) ($MN)
Table 23 Global Dry Eye Syndrome Treatment Market Outlook, By Cequa (2021-2030) ($MN)
Table 24 Global Dry Eye Syndrome Treatment Market Outlook, By Eysuvis (2021-2030) ($MN)
Table 25 Global Dry Eye Syndrome Treatment Market Outlook, By Tyrvaya (2021-2030) ($MN)
Table 26 Global Dry Eye Syndrome Treatment Market Outlook, By Other Drugs (2021-2030) ($MN)
Table 27 Global Dry Eye Syndrome Treatment Market Outlook, By Diagnosis (2021-2030) ($MN)
Table 28 Global Dry Eye Syndrome Treatment Market Outlook, By Tear Osmolarity Test (2021-2030) ($MN)
Table 29 Global Dry Eye Syndrome Treatment Market Outlook, By Schirmer Test (2021-2030) ($MN)
Table 30 Global Dry Eye Syndrome Treatment Market Outlook, By Comprehensive Eye Exam (2021-2030) ($MN)
Table 31 Global Dry Eye Syndrome Treatment Market Outlook, By Medication Type (2021-2030) ($MN)
Table 32 Global Dry Eye Syndrome Treatment Market Outlook, By Over the counter (OTC) Drug (2021-2030) ($MN)
Table 33 Global Dry Eye Syndrome Treatment Market Outlook, By Prescription (Rx) Drug (2021-2030) ($MN)
Table 34 Global Dry Eye Syndrome Treatment Market Outlook, By Other Medication Types (2021-2030) ($MN)
Table 35 Global Dry Eye Syndrome Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 36 Global Dry Eye Syndrome Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 37 Global Dry Eye Syndrome Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 38 Global Dry Eye Syndrome Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 39 Global Dry Eye Syndrome Treatment Market Outlook, By End User (2021-2030) ($MN)
Table 40 Global Dry Eye Syndrome Treatment Market Outlook, By Homecare (2021-2030) ($MN)
Table 41 Global Dry Eye Syndrome Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
Table 42 Global Dry Eye Syndrome Treatment Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 43 Global Dry Eye Syndrome Treatment Market Outlook, By Other End Users (2021-2030) ($MN)